Version history

{
  "session_id": "sess_AD-MASTER-PLAN-GFAP-20260428030756_task_66f1207e_ctx",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "scidex.core.llm.complete",
  "action": "critique",
  "content": "Skeptic critique for analysis AD-MASTER-PLAN-GFAP-20260428030756: AD Master Plan preregistration: GFAP\n\nThe analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: GFAP is a state marker more than a specific intervention point, and reactive astrocytes can be protective or harmful.\n\nThe debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across GFAP, AD, tau, amyloid. Third, an analysis that lacks provenance, environment capture, or preregistered endpoints can produce plausible but non-reproducible conclusions.\n\nA decisive falsifier would be failure of resolve GFAP-positive astrocyte subtypes by spatial transcriptomics and perturb metabolic support pathways in neuron-astrocyte systems to move the predicted proximal endpoint under adequate power and controls. The strongest alternative explanation is that the observed signal is a disease-stage marker, prompt or notebook artifact, or compensatory response rather than an upstream driver.",
  "tokens_used": "299",
  "persona_id": "persona-skeptic"
}